Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113493 | 0.87 | SYK (0.44) | SYKPPARACTSSCTSKATM | |
| SCHEMBL30771227 | 0.83 | SYK (0.46) | SYKPPARACTSSCTSKATM | |
| SCHEMBL31389110 | 0.83 | SYK (0.46) | SYKCTSSCTSKATMACE | |
| SCHEMBL31724128 | 0.83 | SYK (0.53) | SYKPPARACTSSCTSKATM | |
| SCHEMBL30771323 | 0.83 | SYK (0.44) | SYKPPARACTSSCTSKATM | |
| SCHEMBL30771236 | 0.79 | SYK (0.50) | SYKPPARACTSKPTGES | |
| SCHEMBL31724095 | 0.78 | SYK (0.43) | SYKCTSSCTSKATMCTSB | |
| SCHEMBL118384 | 0.78 | CTSK (0.51) | SYKPPARACTSSCTSKATM | |
| SCHEMBL266021 | 0.78 | CTSK (0.51) | SYKPPARACTSSCTSKATM | |
| SCHEMBL266022 | 0.78 | CTSK (0.51) | SYKPPARACTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3354643-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2020-04-30 | — | — | US | disclosed |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180244666-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-30 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424842-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424857-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-20180244666-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | SYK 1404/4885PPARA 4205/4885CTSS 745/4885 |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | SYK 4355/4885PPARA 3431/4885CTSS 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.